KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Total Debt (2023 - 2025)

Biocryst Pharmaceuticals' Total Debt history spans 8 years, with the latest figure at $38.5 million for Q4 2025.

  • For Q4 2025, Total Debt fell 88.94% year-over-year to $38.5 million; the TTM value through Dec 2025 reached $38.5 million, down 88.94%, while the annual FY2025 figure was $38.5 million, 88.94% down from the prior year.
  • Total Debt reached $38.5 million in Q4 2025 per BCRX's latest filing, down from $232.1 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $349.7 million in Q1 2025 to a low of $38.5 million in Q4 2025.
  • Average Total Debt over 3 years is $285.1 million, with a median of $312.4 million recorded in 2023.
  • Peak YoY movement for Total Debt: soared 43.86% in 2024, then crashed 88.94% in 2025.
  • A 3-year view of Total Debt shows it stood at $326.8 million in 2023, then increased by 6.35% to $347.5 million in 2024, then plummeted by 88.94% to $38.5 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Total Debt are $38.5 million (Q4 2025), $232.1 million (Q3 2025), and $278.5 million (Q2 2025).